Skip to main content
AmigoFish

Pharmaceutical Executive Daily: FDA Approves Tukysa Plus Trastuzumab and Pertuzumab

From Pharmaceutical Executive · · 2 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Caribou Biosciences discontinues its two allogeneic CAR-T programs, Kamal Biswas makes the case for continuous quality management maturity, and FDA approves Pfizer’s Tukysa as a first-line maintenance therapy in HER2-positive breast cancer.

Back to Pharmaceutical Executive · Report a problem